Community-Acquired Bacterial Pneumonia - Product Development Milestones
Featured News & Press Releases
Mar 13, 2014: TaiGen Biotechnology Receives Marketing Approval from the Taiwan Food and Drug Administration for Taigexyn in Taiwan
Feb 20, 2014: Cempra Initiates Solithromycin Pediatric Program
Dec 23, 2013: TaiGen Biotechnology Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Nemonoxacin
Dec 16, 2013: Cempra Provides Update on Clinical Development of Solithromycin
Sep 10, 2013: Cempra to Present Data at ICAAC on Solithromycin's Activity Against a Broad Range of Pathogens Including Four Proposed or Designated by the Food and Drug Administration as Qualified Infectious Disease Pathogens Under the Generating Antibiotic Incentives Now Act
Sep 06, 2013: Cempra's Solithromycin Receives Qualified Infectious Disease Product Designation From the U.S. Food and Drug Administration
Aug 14, 2013: Theravance Announces Reintroduction of VIBATIV to the U.S. Market
Jun 13, 2013: Cempra Provides Guidance On Phase III Clinical Program Required For Regulatory Approval Of Solithromycin For Community-Acquired Bacterial Pneumonia
May 28, 2013: Cempra Receives $58m Contract To Develop Antibiotic For Pediatric Use And Biodefense From BARDA
May 20, 2013: Cempra Presents Post-Phase II Analysis Of Solithromycin's Efficacy And Safety Results From Patients With Community Acquired Bacterial Pneumonia
Expert Panel Validation
List of Tables
Number of Products under Development for Community-Acquired Bacterial Pneumonia, H1 2014
Number of Products under Development for Community-Acquired Bacterial Pneumonia - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Global Markets Direct’s, ‘Community-Acquired Bacterial Pneumonia - Pipeline Review, H1 2014’, provides an overview of the Community-Acquired Bacterial Pneumonia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Community-Acquired Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community-Acquired Bacterial Pneumonia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report provides a snapshot of the global therapeutic landscape of Community-Acquired Bacterial Pneumonia
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Community-Acquired Bacterial Pneumonia and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Community-Acquired Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Community-Acquired Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Community-Acquired Bacterial Pneumonia
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Community-Acquired Bacterial Pneumonia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Melinta Therapeutics, Inc Cubist Pharmaceuticals, Inc. Nabriva Therapeutics AG Tetraphase Pharmaceuticals Inc. Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Furiex Pharmaceuticals, Inc. Biota Pharmaceuticals, Inc.